Biofrontera (BFRI) Competitors $1.07 +0.03 (+2.88%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.06 -0.01 (-0.47%) As of 10/3/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BFRI vs. MRSN, XFOR, PLUR, ADAP, SNTI, OKUR, MURA, RANI, EGRX, and ATHEShould you be buying Biofrontera stock or one of its competitors? The main competitors of Biofrontera include Mersana Therapeutics (MRSN), X4 Pharmaceuticals (XFOR), Pluri (PLUR), Adaptimmune Therapeutics (ADAP), Senti Biosciences (SNTI), OnKure Therapeutics (OKUR), Mural Oncology (MURA), Rani Therapeutics (RANI), Eagle Pharmaceuticals (EGRX), and Alterity Therapeutics (ATHE). These companies are all part of the "pharmaceutical products" industry. Biofrontera vs. Its Competitors Mersana Therapeutics X4 Pharmaceuticals Pluri Adaptimmune Therapeutics Senti Biosciences OnKure Therapeutics Mural Oncology Rani Therapeutics Eagle Pharmaceuticals Alterity Therapeutics Mersana Therapeutics (NASDAQ:MRSN) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation. Do institutionals & insiders believe in MRSN or BFRI? 93.9% of Mersana Therapeutics shares are owned by institutional investors. Comparatively, 10.1% of Biofrontera shares are owned by institutional investors. 13.0% of Mersana Therapeutics shares are owned by insiders. Comparatively, 4.8% of Biofrontera shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, MRSN or BFRI? Mersana Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Do analysts prefer MRSN or BFRI? Mersana Therapeutics presently has a consensus price target of $56.60, indicating a potential upside of 583.57%. Biofrontera has a consensus price target of $2.75, indicating a potential upside of 157.01%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Mersana Therapeutics is more favorable than Biofrontera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mersana Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer MRSN or BFRI? In the previous week, Biofrontera had 1 more articles in the media than Mersana Therapeutics. MarketBeat recorded 2 mentions for Biofrontera and 1 mentions for Mersana Therapeutics. Biofrontera's average media sentiment score of 0.37 beat Mersana Therapeutics' score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mersana Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biofrontera 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, MRSN or BFRI? Biofrontera has higher revenue and earnings than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMersana Therapeutics$34.77M1.19-$69.19M-$14.62-0.57Biofrontera$37.32M0.29-$17.76M-$2.26-0.47 Is MRSN or BFRI more profitable? Biofrontera has a net margin of -42.34% compared to Mersana Therapeutics' net margin of -212.94%. Mersana Therapeutics' return on equity of 0.00% beat Biofrontera's return on equity.Company Net Margins Return on Equity Return on Assets Mersana Therapeutics-212.94% N/A -54.85% Biofrontera -42.34%-1,104.09%-82.28% SummaryMersana Therapeutics beats Biofrontera on 9 of the 16 factors compared between the two stocks. Get Biofrontera News Delivered to You Automatically Sign up to receive the latest news and ratings for BFRI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BFRI vs. The Competition Export to ExcelMetricBiofronteraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.54M$3.33B$6.08B$10.54BDividend YieldN/A2.27%5.68%4.70%P/E Ratio-0.4722.1478.0526.71Price / Sales0.29421.51579.60179.64Price / CashN/A47.2037.7961.25Price / Book1.889.9312.556.56Net Income-$17.76M-$52.80M$3.31B$277.70M7 Day Performance11.47%5.22%4.28%2.41%1 Month Performance27.55%13.01%7.85%9.30%1 Year Performance11.46%25.18%71.37%31.22% Biofrontera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BFRIBiofrontera2.2891 of 5 stars$1.07+2.9%$2.75+157.0%-7.8%$10.54M$37.32M-0.4770Short Interest ↓Gap DownMRSNMersana Therapeutics4.0343 of 5 stars$7.76-0.4%$56.60+629.4%-83.6%$38.88M$34.77M-0.53150XFORX4 Pharmaceuticals4.0157 of 5 stars$3.42+2.1%$34.17+899.0%-81.6%$38.22M$32.77M-0.2380Positive NewsPLURPluri1.7445 of 5 stars$4.48-2.8%$12.00+167.9%-14.7%$37.60M$1.34M-0.87150Negative NewsADAPAdaptimmune Therapeutics2.1702 of 5 stars$0.13-7.1%$1.35+939.7%-82.8%$37.11M$65.09M-0.20490SNTISenti Biosciences2.0007 of 5 stars$1.41+0.7%$8.50+502.8%-27.3%$36.62M$2.56M-0.164OKUROnKure Therapeutics3.3333 of 5 stars$2.75+3.0%$32.33+1,075.8%N/A$36.12MN/A-0.57N/AHigh Trading VolumeMURAMural Oncology3.0849 of 5 stars$2.07-0.5%$12.00+479.7%-35.0%$36.04MN/A-0.24119RANIRani Therapeutics3.2598 of 5 stars$0.50+2.0%$7.33+1,367.3%-78.0%$35.22M$1.03M-0.55110Short Interest ↓Gap UpEGRXEagle Pharmaceuticals1.4714 of 5 stars$2.70-4.4%N/A+40.2%$35.07M$257.55M0.00100Gap DownATHEAlterity Therapeutics2.732 of 5 stars$3.76-4.6%$12.00+219.1%+193.1%$34.94MN/A0.0010High Trading Volume Related Companies and Tools Related Companies MRSN Competitors XFOR Competitors PLUR Competitors ADAP Competitors SNTI Competitors OKUR Competitors MURA Competitors RANI Competitors EGRX Competitors ATHE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BFRI) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredLost Decade warning – do this nowWith the Magnificent 7 trading at bubble-like valuations, another “Lost Decade” could be looming — but Porter ...Porter & Company | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biofrontera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
